SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc. has submitted its response to the U.S. Food and Drug Administration (FDA) complete response letter for an over-the-counter (OTC) ZEGERID® branded omeprazole/sodium bicarbonate product with the dosage strength of 20 mg of omeprazole. Schering-Plough received the complete response letter in January 2009 for its New Drug Application (NDA) seeking approval to sell ZEGERID in the U.S. OTC heartburn market.
